- Trial Phase
- Phase 2 (completed) for the FDA drug path; marketed OTC as a supplement
- Time to Market
- Already on the market today as an OTC supplement; FDA drug approval (if the Phase 3 path is pursued) is several years away since Phase 3 has not yet begun.
- Why 4/10
- No hard, dated binary in the next ~12 months: Travelan's FDA End-of-Phase 2 meeting has already occurred and a Phase 3 start has no scheduled date, while the drug is already commercialized OTC — so quarterly sales (not a regulatory decision) are the main share-price driver, capping the score at 4.
For a non-medical investor, Travelan is best framed as a small, growing OTC consumer-health business, not a pending FDA-approval lottery — the defining regulatory catalysts for it have either passed (End-of-Phase 2 meeting) or are unscheduled. Watch the quarterly Travelan sales numbers and any announced Phase 3 design/FDA alignment for IMM-124E; note that the company's next big value event is actually its separate IMM-529 C. difficile program and the partnership search around it, not Travelan.
Price Chart
Executive Summary
Travelan is Immuron's flagship product — an over-the-counter immune supplement made from cow colostrum (first milk) containing antibodies against the E. coli (ETEC) that causes travelers' diarrhea. It is already sold in the US, Australia, Canada and elsewhere, with global FY2026 (ended June 30, 2026) sales of ~AUD$7.7 million, up 6% year-over-year on four straight quarters of growth. Separately, Immuron is pursuing the same active ingredient (IMM-124E) as a regulated FDA drug: a Phase 2 controlled human infection trial (NCT05933525, n=63) is complete and a Phase 2 study report was submitted to the FDA, but a large US military trial (P2TD, n=851) of a third-party-manufactured version missed its primary endpoint, which the company blamed on non-standard dosing and poor compliance. The stock trades around $1.15 with thin coverage (one analyst, ~$3.96 target) — real commercial momentum, but regulatory upside remains years away and unproven.
How It Works
Travelan is a powder made from the colostrum of cows immunized against diarrhea-causing E. coli. It delivers concentrated antibodies that coat the bacteria and their toxins inside the gut so they cannot attach to the intestinal wall and cause diarrhea — a form of passive immunity that works locally in the digestive tract rather than entering the bloodstream.
Trial Status
FDA IND for Travelan/IMM-124E to prevent ETEC travelers' diarrhea is active (approved ~Nov 2022). The Phase 2 controlled human infection trial (NCT05933525, n=63, once-daily dosing) is COMPLETED and a Phase 2 Clinical Study Report was submitted to the FDA showing immunology/microbiome results. The End-of-Phase 2 meeting with the FDA has been held, with the company reverting to a three-times-daily dosing regimen after the n=851 Uniformed Services University military trial (P2TD) of a third-party-made product failed its primary endpoint.
The Two-Sided Case
Upcoming Catalysts
- Any announced Phase 3 trial start or FDA-agreed pivotal design for Travelan/IMM-124E (no date yet)
- Quarterly Travelan sales updates (next FY27 quarterly release), which have been the stock's main recent driver
- IMM-529 (C. difficile) IND review and partnering process — a separate molecule but the same company, and likely the bigger binary
- PDUFA/readouts: none scheduled for Travelan in the next 12 months
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Immuron Ltd 6-K IMRN ·Originating report